COVID-19 in 96 Patients With Hematologic Disease: The First Single-center Experience From the Czech Republic

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F21%3A73608218" target="_blank" >RIV/61989592:15310/21:73608218 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/21:73608218

Výsledek na webu

<a href="https://www.clinical-lymphoma-myeloma-leukemia.com/action/showPdf?pii=S2152-2650%2821%2900176-2" target="_blank" >https://www.clinical-lymphoma-myeloma-leukemia.com/action/showPdf?pii=S2152-2650%2821%2900176-2</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.clml.2021.04.016" target="_blank" >10.1016/j.clml.2021.04.016</a>

Jazyk výsledku

angličtina

Název v původním jazyce

COVID-19 in 96 Patients With Hematologic Disease: The First Single-center Experience From the Czech Republic

Popis výsledku v původním jazyce

Coronavirus disease 2019 (COVID-19) represents an important infectious complication in patients with hematologic diseases. Our study presents first single-center experience from the Czech Republic in 96 patients in whom COVID-19 was confirmed. The study results confirm the prognostic significance of age for achieving treatment response of hematologic disease as well as the severity and mortality of COVID-19 in hematology patients. Background: Coronavirus disease 2019 (COVID-19) represents an important infectious complication associated with high mortality rates in patients with hematologic diseases. There have not been published any epidemiologic studies from Czech Republic so far. Patients and Methods: This study is the first analysis of patients with hematologic malignancies and bone marrow failure syndromes treated at single hematology center in the Czech Republic between March 1 and December 31, 2020, in whom COVID-19 infection was confirmed. Results: The sample comprised 96 patients aged 26 to 84 years (median, 66.0 years). At the time of their COVID-19 diagnosis, 75 patients (78.1%) were treated for hematologic diseases. Twenty-seven patients (28.1%) in the sample had complete remission (CR) of their hematologic disease. They were nonsignificantly more likely to have asymptomatic to moderate COVID-19 infection than those who failed to achieve CR (74.1% vs. 56.5%; P = .06). A more severe course of the infection was significantly correlated with older age (P = .047). Lung involvement was also statistically significantly associated with older age (P = .045). Over the study period, a total of 15 patients died. Age greater than 60 years was significantly associated with deaths from COVID-19 (P = .036), with failure to achieve CR having a statistically nonsignificant impact on mortality (P = .22). Conclusion: These results confirm the prognostic significance of age for achieving treatment response of hematologic disease as well as the severity and mortality of COVID-19 in hematology patients.

Název v anglickém jazyce

COVID-19 in 96 Patients With Hematologic Disease: The First Single-center Experience From the Czech Republic

Popis výsledku anglicky

Coronavirus disease 2019 (COVID-19) represents an important infectious complication in patients with hematologic diseases. Our study presents first single-center experience from the Czech Republic in 96 patients in whom COVID-19 was confirmed. The study results confirm the prognostic significance of age for achieving treatment response of hematologic disease as well as the severity and mortality of COVID-19 in hematology patients. Background: Coronavirus disease 2019 (COVID-19) represents an important infectious complication associated with high mortality rates in patients with hematologic diseases. There have not been published any epidemiologic studies from Czech Republic so far. Patients and Methods: This study is the first analysis of patients with hematologic malignancies and bone marrow failure syndromes treated at single hematology center in the Czech Republic between March 1 and December 31, 2020, in whom COVID-19 infection was confirmed. Results: The sample comprised 96 patients aged 26 to 84 years (median, 66.0 years). At the time of their COVID-19 diagnosis, 75 patients (78.1%) were treated for hematologic diseases. Twenty-seven patients (28.1%) in the sample had complete remission (CR) of their hematologic disease. They were nonsignificantly more likely to have asymptomatic to moderate COVID-19 infection than those who failed to achieve CR (74.1% vs. 56.5%; P = .06). A more severe course of the infection was significantly correlated with older age (P = .047). Lung involvement was also statistically significantly associated with older age (P = .045). Over the study period, a total of 15 patients died. Age greater than 60 years was significantly associated with deaths from COVID-19 (P = .036), with failure to achieve CR having a statistically nonsignificant impact on mortality (P = .22). Conclusion: These results confirm the prognostic significance of age for achieving treatment response of hematologic disease as well as the severity and mortality of COVID-19 in hematology patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Lymphoma, Myeloma and Leukemia

ISSN

2152-2669

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

606-612

Kód UT WoS článku

000690403800013

EID výsledku v databázi Scopus

2-s2.0-85108190391